Exicure Stock Price, News & Analysis (NASDAQ:XCUR) $0.47 +0.01 (+2.17%) (As of 12/1/2023 ET) Add Compare Share Share Today's Range$0.46▼$0.4850-Day Range$0.46▼$0.7852-Week Range$0.44▼$1.78Volume5,699 shsAverage Volume15,011 shsMarket Capitalization$4.07 millionP/E Ratio0.28Dividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainability Exicure MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy3.00% of Float Sold ShortDividend StrengthN/ASustainability-0.67Upright™ Environmental ScoreNews Sentiment0.93Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.14 out of 5 stars N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Exicure. Previous Next 3.0 Short Interest Percentage of Shares Shorted3.00% of the float of Exicure has been sold short.Short Interest Ratio / Days to CoverExicure has a short interest ratio ("days to cover") of 9.Change versus previous monthShort interest in Exicure has recently decreased by 2.44%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldExicure does not currently pay a dividend.Dividend GrowthExicure does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreExicure has received a 74.39% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is mostly driven by its "Preclinical research services for mental health", "Clinical research services for cancer", and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Exicure is -0.67. Previous Next 2.7 News and Social Media Coverage News SentimentExicure has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.76 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Exicure this week, compared to 0 articles on an average week. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Exicure insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.90% of the stock of Exicure is held by insiders.Percentage Held by Institutions46.91% of the stock of Exicure is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Exicure is 0.28, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 116.64.Price to Earnings Ratio vs. SectorThe P/E ratio of Exicure is 0.28, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 129.05.Price to Book Value per Share RatioExicure has a P/B Ratio of 0.16. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Exicure Stock (NASDAQ:XCUR)Exicure, Inc., an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.Read More XCUR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart XCUR Stock News HeadlinesNovember 28, 2023 | msn.comExicure receives Nasdaq delinquency notice on late filing of its form 10-QNovember 9, 2023 | morningstar.comExicure Inc XCURDecember 3, 2023 | Wealthpress (Ad)Trading Experts Call It “The Perfect Tesla Trade”Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.August 29, 2023 | finance.yahoo.comLacklustre Performance Is Driving Exicure, Inc.'s (NASDAQ:XCUR) 25% Price DropAugust 23, 2023 | msn.comExicure names new CEO, CFO, directors in wake of resignationsAugust 15, 2023 | finance.yahoo.comExicure First Half 2023 Earnings: US$1.38 loss per share (vs US$3.71 loss in 1H 2022)August 11, 2023 | marketwatch.comExicure: Substantial Financing Needed to Continue OperationsAugust 11, 2023 | businesswire.comExicure, Inc. Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateDecember 3, 2023 | Wealthpress (Ad)Trading Experts Call It “The Perfect Tesla Trade”Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.July 14, 2023 | finance.yahoo.comExicure, Inc. Reports First Quarter 2023 Financial Results and Provides Corporate UpdateMay 26, 2023 | msn.comExicure board backs CEO Kim's strategic alternative view for companyMay 26, 2023 | finance.yahoo.comExicure, Inc. Announces Support of CEO in its Ongoing Exploration of Strategic AlternativesMay 25, 2023 | sg.finance.yahoo.comExicure, Inc. (XCUR) stock price, news, quote & history – Yahoo FinanceMay 19, 2023 | seekingalpha.comExicure gets Nasdaq non-compliance notice for not filing 10-QApril 27, 2023 | finance.yahoo.comExicure, Inc. Announces Appointment of New CEO and CFO and Changes to Board of DirectorsMarch 28, 2023 | wsj.comExicure Warns of Need to Raise Additional Funds to Keep OperatingMarch 28, 2023 | finance.yahoo.comExicure, Inc. Reports Full Year 2022 Financial Results and Provides Corporate UpdateMarch 20, 2023 | investing.comExicure (XCUR) Earnings Dates & ReportsJanuary 15, 2023 | finance.yahoo.comExicure, Inc. (XCUR) Stock Historical Prices & Data - Yahoo FinanceNovember 15, 2022 | marketwatch.comExicure Warns of Needing Bankruptcy Protection if Deal with CBI USA FailsNovember 15, 2022 | ca.finance.yahoo.comExicure, Inc. Reports Third Quarter 2022 Financial Results and Provides Corporate UpdateSeptember 28, 2022 | finance.yahoo.comExicure Lays Off Two-Third Employees, Ceases R&D ActivitiesSeptember 27, 2022 | uk.investing.comJabil, TD Synnex And 3 Stocks To Watch Heading Into Tuesday By Benzinga - Investing.com UKSeptember 26, 2022 | benzinga.comExicure shares are trading higher after the company announced a workforce reduction and a private placeme - BenzingaSeptember 26, 2022 | investing.comAfter-Hours Movers: Nautilus Gains on Strategic Review By Investing.com - Investing.comSeptember 26, 2022 | seekingalpha.comExicure to get $5.4M equity financing, reduce workforce & end R&D, preclinical activities - Seeking AlphaSeptember 26, 2022 | businesswire.comExicure, Inc. Enters Into Definitive Agreement With CBI USA, Inc. for $5.4 Million Equity Financing and Announces Implementation of Strategic Measure to Reduce Cash Burn and Prioritize Strategic Alternatives - Business WireSee More Headlines Receive XCUR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Exicure and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/19/2021Today12/03/2023Next Earnings (Estimated)12/04/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:XCUR CUSIPN/A CIK1698530 Webwww.exicuretx.com Phone(847) 673-1700FaxN/AEmployees7Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)$1.68 Trailing P/E Ratio0.28 Forward P/E RatioN/A P/E GrowthN/ANet Income$-2,580,000.00 Net MarginsN/A Pretax Margin13.76% Return on Equity34.49% Return on Assets13.07% Debt Debt-to-Equity RatioN/A Current Ratio2.56 Quick Ratio2.56 Sales & Book Value Annual Sales$28.83 million Price / Sales0.14 Cash FlowN/A Price / Cash FlowN/A Book Value$3.00 per share Price / Book0.16Miscellaneous Outstanding Shares8,650,000Free Float8,311,000Market Cap$4.07 million OptionableNot Optionable Beta1.18 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesMr. Paul Kang (Age 61)CEO & Director Ms. Jiyoung Hwang (Age 46)CFO & Director Mr. Joshua Miller (Age 47)Chief Accounting Officer Mr. Bart AndersonSenior Director of R&DKey CompetitorsBlue Water BiotechNASDAQ:BWVMonopar TherapeuticsNASDAQ:MNPRRevelation BiosciencesNASDAQ:REVBLucy Scientific DiscoveryNASDAQ:LSDISoligenixNASDAQ:SNGXView All CompetitorsInsidersCbi Usa, Inc.Bought 3,400,000 shares on 12/15/2022Total: $5.44 M ($1.60/share)View All Insider Transactions XCUR Stock Analysis - Frequently Asked Questions How have XCUR shares performed in 2023? Exicure's stock was trading at $1.15 on January 1st, 2023. Since then, XCUR shares have decreased by 59.1% and is now trading at $0.4701. View the best growth stocks for 2023 here. When is Exicure's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, December 4th 2023. View our XCUR earnings forecast. How were Exicure's earnings last quarter? Exicure, Inc. (NASDAQ:XCUR) posted its quarterly earnings results on Friday, November, 19th. The company reported ($8.10) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($2.70) by $5.40. The business had revenue of ($3.68) million for the quarter, compared to analyst estimates of $0.80 million. When did Exicure's stock split? Exicure's stock reverse split on the morning of Thursday, June 30th 2022. The 1-30 reverse split was announced on Thursday, June 30th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, June 30th 2022. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. How do I buy shares of Exicure? Shares of XCUR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:XCUR) was last updated on 12/3/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Exicure, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.